New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Synthetic control arms: full impact yet to be realised
Amid the brighter spotlights being directed at data use in clinical trials, synthetic control arms represent a unique approach. Synthetic…
-
Scancell shares up 6% after NHS partnership for fast-track cancer vaccine trial
Patients with an advanced type of skin melanoma in England will be given expedited access to a new vaccine being…
-
Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is charting rocky waters as it looks to secure a partner to advance its liver cancer drug through…
-
Global funding cuts reversing decades of tuberculosis progress, WHO says
Ahead of World Tuberculosis Day on 24 March, the World Health Organization (WHO) has said that cuts in global funding…
-
Unsafe and unregulated cell therapies being sold in Europe
The European Medicines Agency (EMA) has issued a warning about the dangers of unregulated advanced therapy medicinal products (ATMPs) being…
-
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the…
-
Why pharma is still far from a treatment for galactosemia
Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA),…
-
Novo Nordisk plans new study for CagriSema, targets 2026 submission
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential…
-
Glucotrack hits trial success for direct blood measuring CGM
Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures glucose levels from a…
